文献速递流行病学与生物统计

肺癌诊断中既往癌症患者领先时间偏倚的估计

Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers.
PubMed 文献 · Stat Med · 2018-04-23

研究提出离散参数模型Logit-Spline/Negative Binomial,联合描述无既往癌症组与既往癌症组的生存,用负二项分布建模领先时间,在SEER-Medicare匹配数据中拟合。以肺癌特异性死亡为终点,I&II期估计平均领先时间约11个月;总生存下I&II期约3.4个月,更高分期两种终点均≤1个月。校正领先时间偏倚会缩小但并非在所有情况下消除既往癌症组的生存优势。

要点

  • I&II期肺癌既往癌症组估计平均领先时间约11个月(肺癌特异性死亡终点)。
  • 总生存终点下I&II期平均领先时间约3.4个月,更高分期≤1个月。
  • 校正领先时间偏倚可缩小但未必完全消除既往癌症组的生存优势。

核心结论

  • 既往癌症者肺癌生存更长可能部分由领先时间偏倚解释,校正后生存优势缩小但并非在所有情况下消失。

研究设计与样本

  • 提出离散参数模型Logit-Spline/Negative Binomial,联合建模无既往癌症组与既往癌症组的生存。
  • 领先时间用负二项分布建模,领先时间后生存用logit风险尺度上的线性样条建模。
  • 模型拟合于SEER-Medicare关联数据集的倾向评分匹配子集,并进行敏感性分析评估关键假设的影响。

主要发现

  • 以肺癌特异性死亡为终点,I&II期患者估计平均领先时间约11个月。
  • 以总生存为终点,I&II期患者估计平均领先时间约3.4个月。
  • 更高分期肺癌患者两种终点的平均领先时间均≤1个月。
  • 校正领先时间偏倚后,既往癌症组存在的生存优势被缩小,但并非所有情况下均被消除。

临床怎么用

  • 解读既往癌症者肺癌生存优势时需考虑领先时间偏倚,避免将其直接归因于真实临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Surprisingly, survival from a diagnosis of lung cancer has been found to be longer for those who experienced a previous cancer than for those with no previous cancer. A possible explanation is lead-time bias, which, by advancing the time of diagnosis, apparently extends survival among those with a previous cancer even when they enjoy no real clinical advantage. We propose a discrete parametric model to jointly describe survival in a no-previous-cancer group (where, by definition, lead-time bias cannot exist) and in a previous-cancer group (where lead-time bias is possible). We model the lead time with a negative binomial distribution and the post-lead-time survival with a linear spline on the logit hazard scale, which allows for survival to differ between groups even in the absence of bias; we denote our model Logit-Spline/Negative Binomial. We fit Logit-Spline/Negative Binomial to a propensity-score matched subset of the Surveillance, Epidemiology, and End Results-Medicare linked data set, conducting sensitivity analyses to assess the effects of key assumptions. With lung cancer-specific death as the end point, the estimated mean lead time is roughly 11 months for stage I&II patients; with overall survival, it is roughly 3.4 months in stage I&II. For patients with higher-stage lung cancers, the mean lead time is 1 month or less for both outcomes. Accounting for lead-time bias reduces the survival advantage of the previous-cancer group when one exists, but it does not nullify it in all cases.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Ge Z, Heitjan DF, Gerber DE, et al. Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers. Stat Med. 2018. PMID: 29687467. doi:10.1002/sim.7691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。